Worcester, MA, May 20, 2016; Biomere is excited and honored to announce that it was one of the companies selected to exhibit its proprietary vaccination platform and lead HSV-2 (Herpes Simplex Virus Type-2) vaccine at this year’s annual BIO International Convention being held June 6-9, 2016 in San Francisco, CA. The 2016 BIO International Convention has partnered with the National Institutes of Health (NIH) and the National Science Foundation (NSF) to feature Small Business Innovation Research (SBIR) funded early-stage companies in the BIO Innovation Zone. The SBIR program provides U.S. federal funding to small businesses engaged in R&D with the potential for commercialization. Companies are rigorously vetted through the NIH and NSF SBIR review process prior to receiving this exhibitory opportunity. Jesus Soriano, a program director for NSF’s SBIR/STTR program previously commented, “The technology behind some of today’s greatest biomedical innovations have come from inventive small companies.” The Innovation Zone, focused on drug discovery, diagnostics and other platform technologies, will provide Biomere and other innovative companies to have the opportunity to exhibit at BIO and be provided the chance to spotlight their company.
“We are extremely excited about being one of the companies to have been selected this year by NIH/NSF. It’s a great chance for Biomere to present our HSV-2 vaccine as well as our expertise and capabilities in vaccine research”, said Dennis Guberski, President and Chairman of Biomere.
“Unlike other approaches, our technology is unique in that it stimulates both mucosal and systemic immune responses and provides immune protection against mucosally transmitted pathogens at targeted mucosal sites. Importantly too, we are able to demonstrate preventative as well as therapeutic efficacy” commented Keijan Yang, PhD, a recognized expert in the field of vaccines. Dr. Yang is the Sr. VP for Vaccine R&D and the primary inventor of the platform technology at Biomere.
About Biomere: Biomere, formerly known as Biomedical Research Models, Inc. is a preclinical CRO based in Worcester, MA focused on providing a customer-focused approach to drug discovery. Founded in 1996, our scientific expertise in metabolic and autoimmune diseases has been recognized by awards of >$25MM in USPHS grants and contracts. In 2014-15, the company embarked on a mission to expand upon its core competencies and establish a full-service, discovery-based CRO.